Related Experiment Videos
[Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2
X Amiot1, J D Grangé, F Boudghene
1Service d'Hépatogastroentérologie, Hôpital Tenon, Paris.
Annales De Gastroenterologie Et D'Hepatologie
|October 1, 1991
Abstract:
Adriamycin is one of the chemotherapeutic agent often administered in the treatment of unresectable hepatocellular carcinoma. On monotherapy, the reported rate response is between 0 to 15 p. cent, without improvement on survival. Its combination with other cytotoxic molecules, such as interferon, has been suggested to improve the percentage of response rates. We present the case of a 73 years old man, who underwent a prolonged partial response of a hepatocellular carcinoma with adriamycin and recombinant human interferon alpha-2.